25 XP   0   0   10

Probiotec Ltd
Buy, Hold or Sell?

Let's analyse Probiotec together

PenkeI guess you are interested in Probiotec Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Probiotec Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Probiotec Ltd

I send you an email if I find something interesting about Probiotec Ltd.

Quick analysis of Probiotec (30 sec.)










What can you expect buying and holding a share of Probiotec? (30 sec.)

How much money do you get?

How much money do you get?
A$0.17
When do you have the money?
1 year
How often do you get paid?
90.0%

What is your share worth?

Current worth
A$1.05
Expected worth in 1 year
A$1.36
How sure are you?
90.0%

+ What do you gain per year?

Total Gains per Share
A$0.57
Return On Investment
20.3%

For what price can you sell your share?

Current Price per Share
A$2.79
Expected price per share
A$2.71 - A$2.94
How sure are you?
50%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1. Valuation of Probiotec (5 min.)




Live pricePrice per Share (EOD)

A$2.79

Intrinsic Value Per Share

A$0.67 - A$2.07

Total Value Per Share

A$1.72 - A$3.12

2. Growth of Probiotec (5 min.)




Is Probiotec growing?

Current yearPrevious yearGrowGrow %
How rich?$56.6m$51.3m$5.2m9.3%

How much money is Probiotec making?

Current yearPrevious yearGrowGrow %
Making money$7.1m$8.9m-$1.7m-24.4%
Net Profit Margin5.1%7.5%--

How much money comes from the company's main activities?

3. Financial Health of Probiotec (5 min.)




3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

What can you expect buying and holding a share of Probiotec? (5 min.)

Welcome investor! Probiotec's management wants to use your money to grow the business. In return you get a share of Probiotec.

What can you expect buying and holding a share of Probiotec?

First you should know what it really means to hold a share of Probiotec. And how you can make/lose money.

Speculation

The Price per Share of Probiotec is A$2.79. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Probiotec.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Probiotec, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$1.05. Based on the TTM, the Book Value Change Per Share is A$0.08 per quarter. Based on the YOY, the Book Value Change Per Share is A$0.13 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.06 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Probiotec.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps0.093.1%0.093.1%0.113.9%0.072.5%0.020.9%
Usd Book Value Change Per Share0.051.8%0.051.8%0.083.0%0.051.9%0.020.6%
Usd Dividend Per Share0.041.5%0.041.5%0.031.1%0.031.2%0.020.7%
Usd Total Gains Per Share0.093.3%0.093.3%0.124.1%0.093.1%0.041.4%
Usd Price Per Share1.82-1.82-1.46-1.39-0.87-
Price to Earnings Ratio21.10-21.10-13.35-25.35-21.36-
Price-to-Total Gains Ratio19.82-19.82-12.69-21.70-16.42-
Price to Book Ratio2.67-2.67-2.31-2.54-1.72-
Price-to-Total Gains Ratio19.82-19.82-12.69-21.70-16.42-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.813221
Number of shares551
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.040.03
Usd Book Value Change Per Share0.050.05
Usd Total Gains Per Share0.090.09
Gains per Quarter (551 shares)50.5947.55
Gains per Year (551 shares)202.38190.22
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
19111119274116180
2182222394148233370
3274334596222349560
4365445798296465750
54565561000370582940
654766712024436981130
763877814045178141320
873088916065919301510
98211001180866510471700
109121112201073911631890

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.01.00.090.0%17.02.02.081.0%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%8.02.00.080.0%18.03.00.085.7%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.00.01.090.0%13.00.08.061.9%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.01.00.090.0%19.02.00.090.5%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

Fundamentals of Probiotec

About Probiotec Ltd

Probiotec Limited engages in the development, manufacture, packing, distribution, and sale of prescription and over the counter pharmaceuticals, complementary medicines and consumer health products, and fast-moving consumer products in Australia and internationally. The company provides contract manufacturing services for solid dose tablets, capsules, and caplets; tablets coatings; blister packs, bottles, sachets, tubs, and tubes; liquids, creams, gels, lotions, ointments, and powders and powder blends. It is also involved in analytical and stability testing services; new product formulation and production trials, and ongoing research and development services; and packaging options for human and animal nutrition products, as well as manufactures and exports a range of nutraceuticals and functional ingredient raw materials. The company was incorporated in 1996 and is headquartered in Laverton North, Australia.

Fundamental data was last updated by Penke on 2024-02-19 12:15:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is fair priced.
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.1. Profitability of Probiotec Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Probiotec earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Probiotec to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 5.1% means that $0.05 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Probiotec Ltd:

  • The MRQ is 5.1%. The company is making a profit. +1
  • The TTM is 5.1%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ5.1%TTM5.1%0.0%
TTM5.1%YOY7.5%-2.4%
TTM5.1%5Y4.9%+0.3%
5Y4.9%10Y0.3%+4.6%
1.1.2. Return on Assets

Shows how efficient Probiotec is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Probiotec to the Drug Manufacturers - Specialty & Generic industry mean.
  • 4.7% Return on Assets means that Probiotec generated $0.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Probiotec Ltd:

  • The MRQ is 4.7%. Using its assets, the company is less efficient in making profit.
  • The TTM is 4.7%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ4.7%TTM4.7%0.0%
TTM4.7%YOY5.8%-1.1%
TTM4.7%5Y3.7%+1.0%
5Y3.7%10Y-0.2%+3.9%
1.1.3. Return on Equity

Shows how efficient Probiotec is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Probiotec to the Drug Manufacturers - Specialty & Generic industry mean.
  • 12.6% Return on Equity means Probiotec generated $0.13 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Probiotec Ltd:

  • The MRQ is 12.6%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 12.6%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ12.6%TTM12.6%0.0%
TTM12.6%YOY17.3%-4.7%
TTM12.6%5Y10.0%+2.7%
5Y10.0%10Y1.0%+9.0%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.2. Operating Efficiency of Probiotec Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Probiotec is operating .

  • Measures how much profit Probiotec makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Probiotec to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 10.0% means the company generated $0.10  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Probiotec Ltd:

  • The MRQ is 10.0%. The company is operating less efficient.
  • The TTM is 10.0%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ10.0%TTM10.0%0.0%
TTM10.0%YOY12.2%-2.3%
TTM10.0%5Y10.1%-0.1%
5Y10.1%10Y3.9%+6.2%
1.2.2. Operating Ratio

Measures how efficient Probiotec is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.97 means that the operating costs are $0.97 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Probiotec Ltd:

  • The MRQ is 0.969. The company is less efficient in keeping operating costs low.
  • The TTM is 0.969. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.969TTM0.9690.000
TTM0.969YOY0.960+0.008
TTM0.9695Y0.963+0.006
5Y0.96310Y0.988-0.026
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.3. Liquidity of Probiotec Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Probiotec is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 0.81 means the company has $0.81 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Probiotec Ltd:

  • The MRQ is 0.808. The company is just not able to pay all its short-term debts. -1
  • The TTM is 0.808. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ0.808TTM0.8080.000
TTM0.808YOY1.451-0.644
TTM0.8085Y1.608-0.800
5Y1.60810Y1.386+0.222
1.3.2. Quick Ratio

Measures if Probiotec is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Probiotec to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.54 means the company can pay off $0.54 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Probiotec Ltd:

  • The MRQ is 0.538. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.538. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.538TTM0.5380.000
TTM0.538YOY1.039-0.501
TTM0.5385Y1.069-0.531
5Y1.06910Y0.804+0.265
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.4. Solvency of Probiotec Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Probiotec assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Probiotec to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.63 means that Probiotec assets are financed with 63.0% credit (debt) and the remaining percentage (100% - 63.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Probiotec Ltd:

  • The MRQ is 0.630. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.630. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.630TTM0.6300.000
TTM0.630YOY0.668-0.038
TTM0.6305Y0.616+0.014
5Y0.61610Y0.511+0.106
1.4.2. Debt to Equity Ratio

Measures if Probiotec is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Probiotec to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 170.2% means that company has $1.70 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Probiotec Ltd:

  • The MRQ is 1.702. The company is just able to pay all its debts with equity.
  • The TTM is 1.702. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.702TTM1.7020.000
TTM1.702YOY2.010-0.308
TTM1.7025Y1.685+0.017
5Y1.68510Y1.186+0.499
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

2. Market Valuation of Probiotec Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Probiotec generates.

  • Above 15 is considered overpriced but always compare Probiotec to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 21.10 means the investor is paying $21.10 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Probiotec Ltd:

  • The EOD is 21.021. Based on the earnings, the company is fair priced.
  • The MRQ is 21.096. Based on the earnings, the company is fair priced.
  • The TTM is 21.096. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD21.021MRQ21.096-0.075
MRQ21.096TTM21.0960.000
TTM21.096YOY13.350+7.747
TTM21.0965Y25.345-4.249
5Y25.34510Y21.358+3.987
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Probiotec Ltd:

  • The EOD is 32.975. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 33.093. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is 33.093. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD32.975MRQ33.093-0.118
MRQ33.093TTM33.0930.000
TTM33.093YOY14.531+18.562
TTM33.0935Y16.133+16.960
5Y16.13310Y27.452-11.319
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Probiotec is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Probiotec Ltd:

  • The EOD is 2.658. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.668. Based on the equity, the company is underpriced. +1
  • The TTM is 2.668. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.658MRQ2.668-0.010
MRQ2.668TTM2.6680.000
TTM2.668YOY2.315+0.353
TTM2.6685Y2.540+0.128
5Y2.54010Y1.716+0.823
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Probiotec Ltd.

3.1. Funds holding Probiotec Ltd

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2021-01-31DFA Asia Pacific Small Company Series0.01-7178--
2021-01-31DFA Investment Dimensions-DFA International Small Cap Growth Port0.01-4147--
Total 0.0201132500.0%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Probiotec Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0780.0780%0.128-40%0.081-4%0.027+189%
Book Value Per Share--1.0501.0500%0.972+8%0.844+24%0.723+45%
Current Ratio--0.8080.8080%1.451-44%1.608-50%1.386-42%
Debt To Asset Ratio--0.6300.6300%0.668-6%0.616+2%0.511+23%
Debt To Equity Ratio--1.7021.7020%2.010-15%1.685+1%1.186+43%
Dividend Per Share--0.0640.0640%0.049+30%0.052+23%0.031+104%
Eps--0.1330.1330%0.169-21%0.109+22%0.037+257%
Free Cash Flow Per Share--0.0850.0850%0.155-45%0.078+9%0.043+95%
Free Cash Flow To Equity Per Share---0.055-0.0550%0.041-235%0.094-158%0.033-265%
Gross Profit Margin---0.249-0.2490%0.165-251%-0.735+196%-2.331+837%
Intrinsic Value_10Y_max--2.067--------
Intrinsic Value_10Y_min--0.674--------
Intrinsic Value_1Y_max--0.173--------
Intrinsic Value_1Y_min--0.050--------
Intrinsic Value_3Y_max--0.545--------
Intrinsic Value_3Y_min--0.166--------
Intrinsic Value_5Y_max--0.949--------
Intrinsic Value_5Y_min--0.299--------
Market Cap226892286.000-2%232445124.800232445124.8000%182977650.000+27%175142643.760+33%109609963.280+112%
Net Profit Margin--0.0510.0510%0.075-32%0.049+6%0.003+1956%
Operating Margin--0.1000.1000%0.122-19%0.101-1%0.039+158%
Operating Ratio--0.9690.9690%0.960+1%0.963+1%0.988-2%
Pb Ratio2.6580%2.6682.6680%2.315+15%2.540+5%1.716+55%
Pe Ratio21.0210%21.09621.0960%13.350+58%25.345-17%21.358-1%
Price Per Share2.7900%2.8002.8000%2.250+24%2.142+31%1.342+109%
Price To Free Cash Flow Ratio32.9750%33.09333.0930%14.531+128%16.133+105%27.452+21%
Price To Total Gains Ratio19.7470%19.81819.8180%12.692+56%21.699-9%16.422+21%
Quick Ratio--0.5380.5380%1.039-48%1.069-50%0.804-33%
Return On Assets--0.0470.0470%0.058-19%0.037+27%-0.002+104%
Return On Equity--0.1260.1260%0.173-27%0.100+27%0.010+1170%
Total Gains Per Share--0.1410.1410%0.177-20%0.133+6%0.058+143%
Usd Book Value--56631063.53856631063.5380%51374267.450+10%44863743.424+26%38321881.414+48%
Usd Book Value Change Per Share--0.0500.0500%0.083-40%0.053-4%0.017+189%
Usd Book Value Per Share--0.6820.6820%0.632+8%0.549+24%0.470+45%
Usd Dividend Per Share--0.0410.0410%0.032+30%0.034+23%0.020+104%
Usd Eps--0.0860.0860%0.110-21%0.071+22%0.024+257%
Usd Free Cash Flow--4564852.1074564852.1070%8183514.154-44%4136665.232+10%2304168.848+98%
Usd Free Cash Flow Per Share--0.0550.0550%0.101-45%0.051+9%0.028+95%
Usd Free Cash Flow To Equity Per Share---0.036-0.0360%0.027-235%0.061-158%0.022-265%
Usd Market Cap147457296.671-2%151066086.608151066086.6080%118917174.735+27%113825204.180+33%71235515.136+112%
Usd Price Per Share1.8130%1.8201.8200%1.462+24%1.392+31%0.872+109%
Usd Profit--7160719.0817160719.0810%8907957.034-20%4755093.435+51%1468698.482+388%
Usd Revenue--139097105.903139097105.9030%118494695.542+17%91398657.774+52%67651162.232+106%
Usd Total Gains Per Share--0.0920.0920%0.115-20%0.086+6%0.038+143%
 EOD+4 -4MRQTTM+0 -0YOY+12 -245Y+22 -1410Y+27 -9

4.2. Fundamental Score

Let's check the fundamental score of Probiotec Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1521.021
Price to Book Ratio (EOD)Between0-12.658
Net Profit Margin (MRQ)Greater than00.051
Operating Margin (MRQ)Greater than00.100
Quick Ratio (MRQ)Greater than10.538
Current Ratio (MRQ)Greater than10.808
Debt to Asset Ratio (MRQ)Less than10.630
Debt to Equity Ratio (MRQ)Less than11.702
Return on Equity (MRQ)Greater than0.150.126
Return on Assets (MRQ)Greater than0.050.047
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Probiotec Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.849
Ma 20Greater thanMa 502.800
Ma 50Greater thanMa 1002.820
Ma 100Greater thanMa 2002.645
OpenGreater thanClose2.750
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-06-302020-06-302021-06-302022-06-302023-06-30
Net Working Capital  27,891-7,35220,5382,81023,348-13923,209-41,234-18,025



Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets235,439
Total Liabilities148,301
Total Stockholder Equity87,138
 As reported
Total Liabilities 148,301
Total Stockholder Equity+ 87,138
Total Assets = 235,439

Assets

Total Assets235,439
Total Current Assets75,668
Long-term Assets159,770
Total Current Assets
Cash And Cash Equivalents 14,050
Net Receivables 36,386
Inventory 23,790
Other Current Assets 1,442
Total Current Assets  (as reported)75,668
Total Current Assets  (calculated)75,668
+/-0
Long-term Assets
Property Plant Equipment 60,987
Goodwill 64,543
Intangible Assets 20,159
Other Assets 14,082
Long-term Assets  (as reported)159,770
Long-term Assets  (calculated)159,770
+/- 0

Liabilities & Shareholders' Equity

Total Current Liabilities93,693
Long-term Liabilities54,608
Total Stockholder Equity87,138
Total Current Liabilities
Short-term Debt 52,562
Short Long Term Debt 46,956
Accounts payable 23,184
Other Current Liabilities 70,509
Total Current Liabilities  (as reported)93,693
Total Current Liabilities  (calculated)193,211
+/- 99,518
Long-term Liabilities
Long term Debt Total 35,334
Other Liabilities 19,273
Long-term Liabilities  (as reported)54,608
Long-term Liabilities  (calculated)54,608
+/- 0
Total Stockholder Equity
Common Stock53,180
Retained Earnings 33,310
Other Stockholders Equity 648
Total Stockholder Equity (as reported)87,138
Total Stockholder Equity (calculated)87,138
+/-0
Other
Capital Stock53,180
Cash And Equivalents14,050
Cash and Short Term Investments 14,050
Common Stock Shares Outstanding 83,016
Current Deferred Revenue-52,562
Liabilities and Stockholders Equity 235,439
Net Debt 73,846
Net Invested Capital 134,094
Net Tangible Assets 2,436
Net Working Capital -18,025
Property Plant and Equipment Gross 101,599
Short Long Term Debt Total 87,896



Balance Sheet

Currency in AUD. All numbers in thousands.

 Trend2023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-30
> Total Assets 
13,986
30,279
48,077
63,911
77,914
85,905
102,258
126,247
106,562
101,165
109,863
104,491
73,007
69,173
71,121
93,657
106,368
134,058
230,876
237,914
235,439
235,439237,914230,876134,058106,36893,65771,12169,17373,007104,491109,863101,165106,562126,247102,25885,90577,91463,91148,07730,27913,986
   > Total Current Assets 
0
0
0
19,897
25,168
29,643
34,900
37,706
26,417
23,384
24,753
22,567
21,662
18,609
21,367
42,626
47,068
46,190
67,776
74,634
75,668
75,66874,63467,77646,19047,06842,62621,36718,60921,66222,56724,75323,38426,41737,70634,90029,64325,16819,897000
       Cash And Cash Equivalents 
0
171
620
3,022
2,028
593
1,673
2,816
938
193
46
1,117
120
506
322
1,816
8,844
6,306
28,427
22,204
14,050
14,05022,20428,4276,3068,8441,8163225061201,117461939382,8161,6735932,0283,0226201710
       Net Receivables 
2,479
5,353
4,832
7,230
7,541
9,641
10,511
12,017
10,250
8,447
11,229
9,648
8,339
8,695
10,822
16,472
18,764
22,939
24,451
31,230
36,386
36,38631,23024,45122,93918,76416,47210,8228,6958,3399,64811,2298,44710,25012,01710,5119,6417,5417,2304,8325,3532,479
       Other Current Assets 
32
43
142
825
480
570
594
389
415
490
261
118
3,321
291
469
12,777
6,205
515
993
1,599
1,442
1,4421,5999935156,20512,7774692913,3211182614904153895945704808251424332
   > Long-term Assets 
0
0
0
44,014
52,746
56,262
67,359
88,541
80,145
77,782
85,109
81,924
51,345
50,564
49,754
51,032
59,300
87,868
163,100
163,280
159,770
159,770163,280163,10087,86859,30051,03249,75450,56451,34581,92485,10977,78280,14588,54167,35956,26252,74644,014000
       Property Plant Equipment 
6,440
16,007
27,861
31,391
34,392
49,891
61,719
78,604
57,665
70,407
60,836
60,834
35,571
26,726
26,642
29,621
17,828
36,593
64,053
62,213
60,987
60,98762,21364,05336,59317,82829,62126,64226,72635,57160,83460,83670,40757,66578,60461,71949,89134,39231,39127,86116,0076,440
       Goodwill 
0
0
1,639
250
250
250
250
5,302
2,079
5,865
7,200
2,079
0
0
0
8,165
8,165
25,541
62,365
64,543
64,543
64,54364,54362,36525,5418,1658,1650002,0797,2005,8652,0795,3022502502502501,63900
       Intangible Assets 
0
0
3,871
5,593
11,465
13,583
15,656
18,681
18,399
28,333
13,887
13,737
10,086
18,817
18,812
10,159
9,255
17,407
21,876
21,536
20,159
20,15921,53621,87617,4079,25510,15918,81218,81710,08613,73713,88728,33318,39918,68115,65613,58311,4655,5933,87100
       Long-term Assets Other 
0
0
0
0
0
0
0
1,116
597
0
0
0
0
0
0
51,032
16,403
-79,541
0
-148,292
-145,689
-145,689-148,2920-79,54116,40351,0320000005971,1160000000
> Total Liabilities 
4,273
14,143
28,551
33,376
39,892
41,825
49,974
52,794
45,246
38,691
46,343
40,170
33,376
25,539
26,555
41,311
56,519
73,549
162,262
158,865
148,301
148,301158,865162,26273,54956,51941,31126,55525,53933,37640,17046,34338,69145,24652,79449,97441,82539,89233,37628,55114,1434,273
   > Total Current Liabilities 
2,953
8,484
20,656
21,425
15,989
21,867
21,287
26,351
39,548
32,962
38,455
30,151
24,259
17,410
16,083
23,877
19,178
25,652
44,428
51,425
93,693
93,69351,42544,42825,65219,17823,87716,08317,41024,25930,15138,45532,96239,54826,35121,28721,86715,98921,42520,6568,4842,953
       Short-term Debt 
0
0
0
12,770
6,447
8,261
7,298
13,719
27,178
21,779
23,631
15,039
12,789
6,445
4,394
6,209
4,467
3,900
7,440
8,653
52,562
52,5628,6537,4403,9004,4676,2094,3946,44512,78915,03923,63121,77927,17813,7197,2988,2616,44712,770000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
17,575
11,736
5,737
3,887
5,571
1,840
1,640
1,560
1,512
46,956
46,9561,5121,5601,6401,8405,5713,8875,73711,73617,57500000000000
       Accounts payable 
1,495
3,520
7,291
5,498
7,066
9,601
7,747
7,862
7,657
7,511
9,390
11,299
8,266
7,284
8,451
10,939
9,382
14,316
13,202
20,547
23,184
23,18420,54713,20214,3169,38210,9398,4517,2848,26611,2999,3907,5117,6577,8627,7479,6017,0665,4987,2913,5201,495
       Other Current Liabilities 
179
335
2,392
435
2,476
4,006
6,241
4,771
4,713
3,672
5,434
3,813
3,204
3,682
3,238
6,729
5,329
11,336
6,550
4,211
70,509
70,5094,2116,55011,3365,3296,7293,2383,6823,2043,8135,4343,6724,7134,7716,2414,0062,4764352,392335179
   > Long-term Liabilities 
0
0
0
11,951
23,903
19,958
28,688
26,443
5,699
5,729
7,889
10,020
9,117
8,129
10,472
17,434
37,341
47,897
117,835
107,440
54,608
54,608107,440117,83547,89737,34117,43410,4728,1299,11710,0207,8895,7295,69926,44328,68819,95823,90311,951000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
2,275
1,013
3,057
8,713
26,248
34,123
89,855
84,341
35,334
35,33484,34189,85534,12326,2488,7133,0571,0132,275000000000000
       Other Liabilities 
0
0
0
51
52
140
926
186
281
348
434
550
6,843
7,115
7,414
8,721
11,093
13,775
27,980
23,099
19,273
19,27323,09927,98013,77511,0938,7217,4147,1156,8435504343482811869261405251000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
6,433
0
0
0
0
0
0
0
0
0
0000000006,43300000000000
> Total Stockholder Equity
9,713
16,137
19,526
30,535
38,022
44,080
52,284
73,453
61,315
62,474
63,519
64,320
39,631
43,635
44,567
52,346
49,849
60,509
68,613
79,049
87,138
87,13879,04968,61360,50949,84952,34644,56743,63539,63164,32063,51962,47461,31573,45352,28444,08038,02230,53519,52616,1379,713
   Common Stock
2,845
6,599
11,163
18,577
20,230
21,204
23,160
36,696
33,687
33,687
33,687
33,687
33,687
33,687
33,687
38,596
33,608
43,737
50,693
51,293
53,180
53,18051,29350,69343,73733,60838,59633,68733,68733,68733,68733,68733,68733,68736,69623,16021,20420,23018,57711,1636,5992,845
   Retained Earnings 
6,868
9,272
4,490
9,247
14,224
20,067
27,606
35,180
23,787
25,229
25,826
26,729
1,987
6,001
7,206
9,533
15,653
16,294
17,852
27,578
33,310
33,31027,57817,85216,29415,6539,5337,2066,0011,98726,72925,82625,22923,78735,18027,60620,06714,2249,2474,4909,2726,868
   Capital Surplus 000000000000000000000
   Treasury Stock000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
3,904
-363
-392
3,674
4,217
587
478
68
178
648
648178684785874,2173,674-392-3633,90400000000000



Balance Sheet

Currency in AUD. All numbers in thousands.




Cash Flow

Currency in AUD. All numbers in thousands.